- Home
- CELC vs AKBA Comparison
CELC vs AKBA Comparison
Compare CELC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- AKBA
- Stock Information
- Founded
- CELC 2011
- AKBA 2007
- Country
- CELC United States
- AKBA United States
- Employees
- CELC N/A
- AKBA N/A
- Industry
- CELC Medical Specialities
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CELC Health Care
- AKBA Health Care
- Exchange
- CELC Nasdaq
- AKBA Nasdaq
- Market Cap
- CELC 327.3M
- AKBA 336.2M
- IPO Year
- CELC 2017
- AKBA 2014
- Fundamental
- Price
- CELC $10.24
- AKBA $2.06
- Analyst Decision
- CELC Strong Buy
- AKBA Strong Buy
- Analyst Count
- CELC 6
- AKBA 3
- Target Price
- CELC $30.17
- AKBA $6.50
- AVG Volume (30 Days)
- CELC 392.7K
- AKBA 5.0M
- Earning Date
- CELC 05-14-2025
- AKBA 05-08-2025
- Dividend Yield
- CELC N/A
- AKBA N/A
- EPS Growth
- CELC N/A
- AKBA N/A
- EPS
- CELC N/A
- AKBA N/A
- Revenue
- CELC N/A
- AKBA $160,180,000.00
- Revenue This Year
- CELC N/A
- AKBA $22.50
- Revenue Next Year
- CELC N/A
- AKBA $43.23
- P/E Ratio
- CELC N/A
- AKBA N/A
- Revenue Growth
- CELC N/A
- AKBA N/A
- 52 Week Low
- CELC $7.58
- AKBA $0.80
- 52 Week High
- CELC $19.77
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- CELC 54.38
- AKBA 56.65
- Support Level
- CELC $7.58
- AKBA $1.52
- Resistance Level
- CELC $10.48
- AKBA $1.86
- Average True Range (ATR)
- CELC 1.04
- AKBA 0.15
- MACD
- CELC 0.17
- AKBA 0.02
- Stochastic Oscillator
- CELC 80.01
- AKBA 88.52
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.